Quantbot Technologies LP Sells 10,781 Shares of DaVita Inc. (NYSE:DVA)

Quantbot Technologies LP cut its stake in shares of DaVita Inc. (NYSE:DVA) by 19.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 43,660 shares of the company’s stock after selling 10,781 shares during the period. Quantbot Technologies LP owned 0.05% of DaVita worth $6,529,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of DVA. Amundi increased its holdings in shares of DaVita by 116.4% in the fourth quarter. Amundi now owns 446,386 shares of the company’s stock worth $68,726,000 after purchasing an additional 240,126 shares during the period. FMR LLC increased its holdings in DaVita by 659.9% during the 3rd quarter. FMR LLC now owns 177,406 shares of the company’s stock valued at $29,082,000 after purchasing an additional 154,061 shares during the period. Skandinaviska Enskilda Banken AB publ lifted its holdings in DaVita by 256.8% in the 4th quarter. Skandinaviska Enskilda Banken AB publ now owns 162,233 shares of the company’s stock worth $24,301,000 after buying an additional 116,758 shares during the period. Glenmede Trust Co. NA boosted its holdings in shares of DaVita by 731.6% during the 3rd quarter. Glenmede Trust Co. NA now owns 123,269 shares of the company’s stock valued at $20,207,000 after buying an additional 108,446 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its position in shares of DaVita by 17.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company’s stock worth $99,846,000 after buying an additional 92,014 shares during the period. 90.12% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on DVA. Barclays upped their price objective on shares of DaVita from $164.00 to $169.00 and gave the stock an “equal weight” rating in a report on Tuesday, February 18th. Cowen reissued a “hold” rating on shares of DaVita in a report on Tuesday, February 18th. Finally, Sanford C. Bernstein set a $184.00 target price on shares of DaVita in a research note on Friday, February 21st. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $166.33.

DaVita Stock Performance

NYSE:DVA opened at $141.23 on Friday. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.21 and a current ratio of 1.26. The stock has a 50-day simple moving average of $159.28 and a two-hundred day simple moving average of $157.79. The firm has a market capitalization of $11.30 billion, a PE ratio of 13.15, a P/E/G ratio of 1.07 and a beta of 0.99. DaVita Inc. has a 52-week low of $125.64 and a 52-week high of $179.60.

DaVita (NYSE:DVA) last released its quarterly earnings data on Thursday, February 13th. The company reported $2.24 earnings per share for the quarter, topping analysts’ consensus estimates of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. Analysts forecast that DaVita Inc. will post 10.76 EPS for the current year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.